Case Background:
This is a federal securities fraud class action lawsuit on behalf of those who purchased or otherwise acquired Neumora Therapeutics, Inc. (“Neumora”) (NASDAQ: NMRA) common stock pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Offering Documents”) issued in connection with Neumora’s initial public offering (“IPO”) on or around September 15, 2023.
Neumora is a clinical-stage biopharmaceutical company with a focus on treating neuropsychiatric and neurodegenerative diseases. Navacaprant, Neumora’s flagship drug candidate, is an oral kappa opioid receptor antagonist for the treatment of mild to moderate major depressive disorder (“MDD”). Neumora acquired Navacaprant, along with other therapeutic candidates, through its acquisition of BlackThorn Therapeutics, Inc. (“BlackThorn”).
The complaint alleges that, in the Offering Documents, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) for Neumora to later justify conducting its phase three program, Neumora amended Navacaprant’s phase two trial inclusion criteria of patients with mild to moderate MDD to include a patient population with moderate to severe MDD; (2) to that same end, Neumora added a prespecified analysis to the phase two statistical analysis plan, focusing on patients with moderate to severe MDD; (3) Navacaprant’s phase two trial failed to achieve statistical significance compared to the placebo at eight weeks for the moderate to severe MDD patient population and lacked adequate data to be able to accurately predict the results of the first study in the phase three program; and (4) as a result of the foregoing, Defendants’ statements about the company’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.
Current Status of Case:
On November 19, 2025, the Court appointed Lead Plaintiff and Lead Counsel. This action is ongoing.
If you wish to discuss this action or have any questions, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453; toll-free at (844) 887-9500; or via e-mail at info@ktmc.com. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.